Towards an optimal TRIPS-compliant industrial policy for the pharmaceutical industry in Bangladesh

Research output: Contribution to conferenceConference paper


Since 1982, under a protective regulatory regime, Bangladesh has attained self-sufficiency in off patent drugs. Of significance, all LDCs including Bangladesh need to implement the Agreement on Trade Related Intellectual Property Rights (TRIPS) of the WTO in 2016. This regulatory change warrants enhanced technology and R&D adoption to improve firms’ competitiveness. Using data
obtained from 94 pharmaceutical companies through a questionnaire survey, this study provides an empirical analysis of firm-level TRIPS-related vulnerability facing the Bangladeshi pharmaceutical sector. I find that R&D-related and international competitiveness-related vulnerabilities are the most important types of vulnerability. A vulnerability-based classification using cluster analysis reveals that the least vulnerable firms have comparatively higher involvement in independent and collaborative R&D activities. However, at the industry level, the inter-firm and firm academia/institution collaboration is significantly low. The study underlines the importance of careful policy intervention to provide sustained institutional support to create incentives for multidimensional
R&D collaboration, including public-private partnerships.


ConferencePublic Policy in the ‘Asian Century’ Conference
Internet address


Dive into the research topics of 'Towards an optimal TRIPS-compliant industrial policy for the pharmaceutical industry in Bangladesh'. Together they form a unique fingerprint.

Cite this